Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Open Access
- 1 November 1994
- journal article
- Published by Environmental Health Perspectives in Environmental Health Perspectives
- Vol. 102 (suppl 9), 55-61
- https://doi.org/10.1289/ehp.94102s955
Abstract
Polymorphisms in many xenobiotic metabolizing enzymes occur leading to variation in the level of enzyme expression in vivo. Enzymes showing such polymorphisms include the cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2A6, CYP2D6, and CYP2E1 and the phase two metabolism enzymes glutathione S-transferase MI (GSTMI) and arylamine N-acetyltransferase 2 (NAT2). In the past, these polymorphisms have been studied by phenotyping using in vivo administration of probe drugs. However, the mutations which give rise to several of these polymorphisms have now been identified and genotyping assays for polymorphisms in CYP1A1, CYP2A6, CYP2D6, CYP2E1, GSTMI, and NAT2 have been developed. Specific phenotypes for several of the polymorphic enzymes have been associated with increased susceptibility to malignancy, particularly lung and bladder cancer, and Parkinson's disease. These associations are likely to be due to altered activation or detoxication of chemicals initiating these diseases, including components of tobacco smoke and neurotoxins. The substrate specificity and tissue distribution of polymorphic enzymes implicated in disease causation discussed with particular reference to previously described disease-phenotype associations.Keywords
This publication has 82 references indexed in Scilit:
- Metabolic polymorphisms affecting activation of toxic and mutagenic arylaminesTrends in Pharmacological Sciences, 1992
- Glutathione S-Transferase and Epoxide Hydrolase Activity in Human Leukocytes in Relation to Risk of Lung Cancer and Other Smoking-Related CancersJNCI Journal of the National Cancer Institute, 1992
- Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesPharmacogenetics, 1991
- Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P45 0IA1 geneFEBS Letters, 1990
- Evidence for two closely related isozymes of arylamine N‐acetyltransferase in human liverFEBS Letters, 1989
- Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22Genomics, 1988
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- N-Acetylation Phenotype in Bladder CancerHuman Toxicology, 1982
- Aryl hydrocarbon hydroxylase inducibility and lymphoblast formation in lung cancer patientsInternational Journal of Cancer, 1979
- Questionable Relation of Aryl Hydrocarbon Hydroxylase to Lung-Cancer RiskNew England Journal of Medicine, 1977